Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
Summary
—In a press conference Wednesday, President Trump signaled willingnessto work with Democrats in Congress on the regulation of drug prices, echoing comments he made before the election.— STAT reported that the drug industry donated record amounts of cash to political campaigns for a midterm cycle and, bucking a decade-long trend, began shifting its largesse to Democrats in the run-up to Election Day.––Shares of Voyager Therapeutics (NASDAQ: VYGR ) fell 12 percent after the company disclosed that a placebo-controlled Phase 2 trial won’t be enough to support an approval application for its experimental gene therapy for Parkinson’s disease.—Johnson & Johnson (NYSE: JNJ ) paid Korean pharmaceutical company Yuhan $50 million upfront for rights to lazertinib, which is aimed at lung cancer that carries an EGFR mutation.—Regulus Therapeutics (NASDAQ: RGLS ) amended its partnership with Sanofi (NYSE: SNY ), granting the French pharma an exclusive worldwide license to its drug mi-R21 for all indications, including Alport syndrome, a rare, inherited kidney disorder.